Allogeneic transplantation for primary myelofibrosis with BM, peripheral blood or umbilical cord blood

An analysis of the JSHCT

M. Murata, T. Nishida, S. Taniguchi, K. Ohashi, H. Ogawa, T. Fukuda, Takehiko Mori, H. Kobayashi, C. Nakaseko, N. Yamagata, Y. Morishima, T. Nagamura-Inoue, H. Sakamaki, Y. Atsuta, R. Suzuki, T. Naoe

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

To determine whether a difference in donor source affects the outcome of transplantation for patients with primary myelofibrosis (PMF), a retrospective study was conducted using the national registry data on patients who received first allogeneic hematopoietic cell transplantation (HCT) with related BM (n=19), related PBSCs (n=25), unrelated BM (n=28) or unrelated umbilical cord blood (UCB; n=11). The 5-year OS rates after related BM, related PBSC and unrelated BM transplantation were 63%, 43% and 41%, respectively, and the 2-year OS rate after UCB transplantation was 36%. On multivariate analysis, the donor source was not a significant factor for predicting the OS rate. Instead, performance status (PS) ≥2 (vs PS 0-1) predicted a lower OS (P=0.044), and RBC transfusion ≥20 times before transplantation (vs transfusion ≤9 times) showed a trend toward a lower OS (P=0.053). No advantage of nonmyeloablative preconditioning regimens in terms of decreasing nonrelapse mortality or increasing OS was found. Allogeneic HCT, and even unrelated BM and UCB transplantation, provides a curative treatment for PMF patients.

Original languageEnglish
Pages (from-to)355-360
Number of pages6
JournalBone Marrow Transplantation
Volume49
Issue number3
DOIs
Publication statusPublished - 2014 Mar

Fingerprint

Primary Myelofibrosis
Homologous Transplantation
Fetal Blood
Transplantation
Cell Transplantation
Tissue Donors
Registries
Multivariate Analysis
Retrospective Studies
Mortality

Keywords

  • donor source
  • engraftment
  • hematopoietic SCT
  • idiopathic myelofibrosis
  • survival

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Allogeneic transplantation for primary myelofibrosis with BM, peripheral blood or umbilical cord blood : An analysis of the JSHCT. / Murata, M.; Nishida, T.; Taniguchi, S.; Ohashi, K.; Ogawa, H.; Fukuda, T.; Mori, Takehiko; Kobayashi, H.; Nakaseko, C.; Yamagata, N.; Morishima, Y.; Nagamura-Inoue, T.; Sakamaki, H.; Atsuta, Y.; Suzuki, R.; Naoe, T.

In: Bone Marrow Transplantation, Vol. 49, No. 3, 03.2014, p. 355-360.

Research output: Contribution to journalArticle

Murata, M, Nishida, T, Taniguchi, S, Ohashi, K, Ogawa, H, Fukuda, T, Mori, T, Kobayashi, H, Nakaseko, C, Yamagata, N, Morishima, Y, Nagamura-Inoue, T, Sakamaki, H, Atsuta, Y, Suzuki, R & Naoe, T 2014, 'Allogeneic transplantation for primary myelofibrosis with BM, peripheral blood or umbilical cord blood: An analysis of the JSHCT', Bone Marrow Transplantation, vol. 49, no. 3, pp. 355-360. https://doi.org/10.1038/bmt.2013.180
Murata, M. ; Nishida, T. ; Taniguchi, S. ; Ohashi, K. ; Ogawa, H. ; Fukuda, T. ; Mori, Takehiko ; Kobayashi, H. ; Nakaseko, C. ; Yamagata, N. ; Morishima, Y. ; Nagamura-Inoue, T. ; Sakamaki, H. ; Atsuta, Y. ; Suzuki, R. ; Naoe, T. / Allogeneic transplantation for primary myelofibrosis with BM, peripheral blood or umbilical cord blood : An analysis of the JSHCT. In: Bone Marrow Transplantation. 2014 ; Vol. 49, No. 3. pp. 355-360.
@article{5b103724d25b44a2aaf89085d0560344,
title = "Allogeneic transplantation for primary myelofibrosis with BM, peripheral blood or umbilical cord blood: An analysis of the JSHCT",
abstract = "To determine whether a difference in donor source affects the outcome of transplantation for patients with primary myelofibrosis (PMF), a retrospective study was conducted using the national registry data on patients who received first allogeneic hematopoietic cell transplantation (HCT) with related BM (n=19), related PBSCs (n=25), unrelated BM (n=28) or unrelated umbilical cord blood (UCB; n=11). The 5-year OS rates after related BM, related PBSC and unrelated BM transplantation were 63{\%}, 43{\%} and 41{\%}, respectively, and the 2-year OS rate after UCB transplantation was 36{\%}. On multivariate analysis, the donor source was not a significant factor for predicting the OS rate. Instead, performance status (PS) ≥2 (vs PS 0-1) predicted a lower OS (P=0.044), and RBC transfusion ≥20 times before transplantation (vs transfusion ≤9 times) showed a trend toward a lower OS (P=0.053). No advantage of nonmyeloablative preconditioning regimens in terms of decreasing nonrelapse mortality or increasing OS was found. Allogeneic HCT, and even unrelated BM and UCB transplantation, provides a curative treatment for PMF patients.",
keywords = "donor source, engraftment, hematopoietic SCT, idiopathic myelofibrosis, survival",
author = "M. Murata and T. Nishida and S. Taniguchi and K. Ohashi and H. Ogawa and T. Fukuda and Takehiko Mori and H. Kobayashi and C. Nakaseko and N. Yamagata and Y. Morishima and T. Nagamura-Inoue and H. Sakamaki and Y. Atsuta and R. Suzuki and T. Naoe",
year = "2014",
month = "3",
doi = "10.1038/bmt.2013.180",
language = "English",
volume = "49",
pages = "355--360",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Allogeneic transplantation for primary myelofibrosis with BM, peripheral blood or umbilical cord blood

T2 - An analysis of the JSHCT

AU - Murata, M.

AU - Nishida, T.

AU - Taniguchi, S.

AU - Ohashi, K.

AU - Ogawa, H.

AU - Fukuda, T.

AU - Mori, Takehiko

AU - Kobayashi, H.

AU - Nakaseko, C.

AU - Yamagata, N.

AU - Morishima, Y.

AU - Nagamura-Inoue, T.

AU - Sakamaki, H.

AU - Atsuta, Y.

AU - Suzuki, R.

AU - Naoe, T.

PY - 2014/3

Y1 - 2014/3

N2 - To determine whether a difference in donor source affects the outcome of transplantation for patients with primary myelofibrosis (PMF), a retrospective study was conducted using the national registry data on patients who received first allogeneic hematopoietic cell transplantation (HCT) with related BM (n=19), related PBSCs (n=25), unrelated BM (n=28) or unrelated umbilical cord blood (UCB; n=11). The 5-year OS rates after related BM, related PBSC and unrelated BM transplantation were 63%, 43% and 41%, respectively, and the 2-year OS rate after UCB transplantation was 36%. On multivariate analysis, the donor source was not a significant factor for predicting the OS rate. Instead, performance status (PS) ≥2 (vs PS 0-1) predicted a lower OS (P=0.044), and RBC transfusion ≥20 times before transplantation (vs transfusion ≤9 times) showed a trend toward a lower OS (P=0.053). No advantage of nonmyeloablative preconditioning regimens in terms of decreasing nonrelapse mortality or increasing OS was found. Allogeneic HCT, and even unrelated BM and UCB transplantation, provides a curative treatment for PMF patients.

AB - To determine whether a difference in donor source affects the outcome of transplantation for patients with primary myelofibrosis (PMF), a retrospective study was conducted using the national registry data on patients who received first allogeneic hematopoietic cell transplantation (HCT) with related BM (n=19), related PBSCs (n=25), unrelated BM (n=28) or unrelated umbilical cord blood (UCB; n=11). The 5-year OS rates after related BM, related PBSC and unrelated BM transplantation were 63%, 43% and 41%, respectively, and the 2-year OS rate after UCB transplantation was 36%. On multivariate analysis, the donor source was not a significant factor for predicting the OS rate. Instead, performance status (PS) ≥2 (vs PS 0-1) predicted a lower OS (P=0.044), and RBC transfusion ≥20 times before transplantation (vs transfusion ≤9 times) showed a trend toward a lower OS (P=0.053). No advantage of nonmyeloablative preconditioning regimens in terms of decreasing nonrelapse mortality or increasing OS was found. Allogeneic HCT, and even unrelated BM and UCB transplantation, provides a curative treatment for PMF patients.

KW - donor source

KW - engraftment

KW - hematopoietic SCT

KW - idiopathic myelofibrosis

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=84904243249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904243249&partnerID=8YFLogxK

U2 - 10.1038/bmt.2013.180

DO - 10.1038/bmt.2013.180

M3 - Article

VL - 49

SP - 355

EP - 360

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 3

ER -